Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameSinco Pharma
Stock Code06833
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities為中國醫藥行業第三大營銷、推廣及渠道管理服務供應商,亦是中國血漿藥品唯一相關服務供應商,為海外中小型製藥商提供綜合營銷、推廣及渠道管理服務。
Listing Date2016-03-10
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國四川省成都市高新區天府大道北段1700號環球中心E5-1805室
Business Address (Hong Kong)香港皇后大道中183號中遠大廈44樓4408A室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.sinco-pharm.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 0.80 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 0.0001 / shares
Offer Period2016-02-29 to 2016-03-03
Global Offering Shares400,000,000 shares
HK Public Offer Shares (Initial)40,000,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)360,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,600,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share6.9%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 320,000,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 312.5M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +3009%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2012201320142015-10
Revenue 26,166532,480950,079850,795
Cost of sales -22,934-471,361-820,309-737,381
Gross profit 3,23261,119129,770113,414
Other income and gains, net 2154,9202,295534
Selling and distribution expenses -225-2,358-6,792-4,186
Administrative expenses -2,673-9,866-17,520-29,838
Operating profit 52951,981100,03869,453
Net finance costs 0-1,062-6,226-6,054
Profit before tax 52950,91993,81263,399
Income tax expense -253-7,932-13,683-12,321
Profit for the year 27642,98780,12951,078
Profit attributable to owners 13836,53969,36751,080
Balance Sheet
Item 2012201320142015-10
Cash and cash equivalents 26,67927,85158,28042,013
Trade and bills receivables 011,40250,0600
Inventories 82,86059,31930,22432,836
Total current assets 112,929273,193288,092173,634
Total assets 122,766376,845441,214418,051
Total current liabilities 117,697328,489317,729242,860
Total liabilities 117,697328,489317,729242,860
Total equity 5,06948,356123,485175,191
Equity attributable to owners 4,30840,847105,214174,894
Interest-bearing borrowings 051,51591,78892,806
Cash Flow Statement
Item 2012201320142015-10
Net cash from operating activities -88977,89953,13725,491
Net cash from investing activities -9,596-89,821-41,628-45,847
Net cash from financing activities 40,40026,24714,3019,904
Net increase in cash 29,91514,32525,810-10,452
Depreciation of PP&E 1951,0061,8784,045
Amortisation of intangible assets 0004,204
Purchase of PP&E -9,596-50,013-33,447-8,245
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 0.8
First Day OpenHK$ 0.9
First Day Change-73.50%
First Day Volume149292000.0
First Day Turnover131237000.0
Use of Proceeds
1、約45%(約146.2百萬港元)將用于(i)收購新產品的銷售及經銷權;及(ii)收購醫藥行業具備專有知識產權或增長潛力的企業; 2、約33%(約107.2百萬港元)將不可撤回地用作償還本集團尚未償還的部分貸款及銀行貿易信貸; 3、約14%(約45.5百萬港元)將用于在四川雙流保稅區開發冷鏈設施及研發基地,預期冷鏈設施竣工后會成為中國西南地區最大的冷鏈設施之一; 4、約8%(約26.0百萬港元)將用作營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Overall Coordinators (1)
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Bookrunners (1)
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Lead Managers (1)
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Prestigious Leader Limited 50,000,000 HKD — 3.90% — 6 months 2016-09-10
2 四川惠丰投资发展有限责任公司 38,758,400 HKD — 3.00% — 6 months 2016-09-10

Directors & Management

PositionChinese nameEnglish Name
Chairman黃祥彬—
Company Secretary高潁妤—
No director data available.

Major Shareholders

Major Shareholders & HoldingsRisun持有1,050,000,000股,佔已發行股本65.625%;黃先生透過Risun持有同等權益。
About this page

This page shows Sinco Pharma (06833) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect